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With advances in therapeutics for rare, genetic and syndromic diseases, there is an increasing need for
objective assessments of phenotypic endpoints. These assessments will preferentially be high precision,
non-invasive, non-irradiating, and relatively inexpensive and portable. We report a case of a child with
an extensive lymphatic vascular malformation of the head and neck, treated with an mammalian target
of Rapamycin (mTOR) inhibitor that was assessed using 3D facial analysis. This case illustrates that this
technology is prospectively a cost-effective modality for treatment monitoring, and it supports that it may
also be used for novel explorations of disease biology for conditions associated with disturbances in the
mTOR, and interrelated, pathways.
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Clinical Report
Three-dimensional (3D) facial analysis (3DFA) is being in-
creasingly investigated for multiple applications, including
for the monitoring of medical therapy of conditions asso-
ciated with craniofacial anomaly (CFA) and dysmorphol-
ogy (Baynam et al., 2013; Kung et al., 2013). Craniofacial
anomalies are a diverse set of congenital and acquired con-
ditions with a significant individual and societal burden;
they are associated with a high incidence of speech, hearing,
oral function, appearance, and socialmorbidity (Leopold&
Rhodes, 2010; Mosey, 2004). The treatment of CFA, prefer-
ably monitored in a non-invasive manner, can ameliorate
this morbidity. Congenital vascular anomalies affect 1.5%
of the general population (Eifert et al., 2000) and they may
be (sub)cutaneous and facial. There are multiple treatment
modalities available for these conditions and they include
drugs that modify angiogenesis; these include mTOR path-
way inhibitors such as rapamycin (Phung et al., 2006).More
broadly, activatingmutations in themTOR, and interacting,
pathways have been associated with developmental brain
anomalies and neurocognitive disorders including tuber-
ous sclerosis complex (TSC) (Crino, 2011). Accordingly,
topical rapamycin has been used for the treatment of facial
angiofibromas in childrenwith TSC (Foster et al., 2012) and
a further inhibitor of the mTOR pathway, everolimus, has
been successfully trialed for an internal organ complication
of this condition (Jozwiak et al., 2012). In this report, we
describe the first assessment by 3DFA of the treatment re-
sponse of a head andneck lymphatic vascularmalformation
to anmTOR inhibitor. This provides further supportive ev-
idence for the potential utility of 3DFA as a non-invasive,
non-irradiating, and relatively inexpensive technique for
monitoring some medical therapies. It might also provide
further perspectives for the investigation of disease biology.
An 11-year-old girl presented with extensive predom-
inantly microcystic lymphatic vascular malformation in-
volving the left cheek, lower lip, tongue, floor of mouth,
laryngeal inlet, and extending inferiorly to the level of the
thoracic inlet. In infancy and early childhood, she had
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FIGURE 1
(Colour online) Frontal, profile and bird’s eye views of the 3D distance dysmorphogram (scale bar 0–5 mm) at T0 pre-treatment. Note.
Dysmorphology is clearly demarcated with distinctive boundaries that may be reflective of underlying compartmentalization of the face
by facial retaining ligaments.
a series of intralesional OK432 injections with moderate
improvement. However, she continued to have significant
episodes of hemorrhage from the tongue and was suffer-
ing socially from her abnormal facial appearance. After an
encouraging publication by Hammill et al. (2011) on the
use of oral mTOR inhibitors for lymphatic malformations,
she was commenced on oral sirolimus 0.8 mg/m2 at twelve
hourly intervals. Her initial dose of 1 mg bd was gradually
adjusted to 2 mg bd to obtain a trough sirolimus level of
10–15ng/mL.Her full bloodpicture, electrolytes, liver func-
tion, fasting lipids, blood pressure, and growth were closely
monitored. 3DFA was performed at baseline, 3 months and
6 months. Subtle improvement was noted clinically within
the first 3 months and was demonstrated at the 3-month
3DFA. A repeat MRI scan was performed after 6 months of
the treatment, which showed a corresponding reduction in
the size of the larger cysts.
Materials and Methods
Facial scans were performed using the 3dMD Facial system
(3dMD Pty Ltd, Atlanta, Georgia, USA) with the subject
sitting with her head held in a natural head position. Scans
were performed prior to the commencement of treatment
(T0), and 3 (T1) and 6 months after the commencement
of treatment (T2). The raw scan data are cleaned of su-
perfluous surfaces prior to processing with a purpose-built
anthropometric mask (AM; Claes et al., 2012b). The AM
is comprised of a spatially dense set of quasi-landmarks;
this mask is fitted to the cleaned raw scan data using a
set of nested fitting algorithms. This effectively anneals the
floating AM to the target 3D scan to establish a manifold
representing a subject’s face that comprises a discrete set of
spatially dense corresponding 3D quasi-landmarks, which
can be used in geometric morphometric analysis. Subse-
quently, facial discordance canbe objectivelymeasuredwith
a robust superimposition of processed scans of a subject’s
face at different treatment time points. The proportion of
the face that is discordant can be summarized as percentage
scores of relative significant discordance (RSD%), where
thresholds can be either arbitrarily set in terms of magni-
tude (millimeters) or on statistical confidence limits based
on the distribution of the found discrepancies. These sta-
tistical outcomes can be visualized by the production of a
facial histogram illustrating regional facial discordances. As
ameasure of the severity of the discordance, the distribution
of discrepancies can be summarized in root mean squared
error (RMSE) score (Claes et al., 2012b).
In addition to quantifying facial discordance between
time points, a measure of facial harmony was made at base-
line and at conclusion of the current treatment cycle utiliz-
ing dysmorphometrics. In this case, the quasi-landmark set
of the mapped patient scan is subject to a robust statistical
superimposition to a quasi-landmark variance/covariance
model (Claes et al., 2012a) derived from a reference set
of facial scans from healthy subjects. This superimposi-
tion simultaneously detects the harmonious (within range)
and disharmonious (outside range) quasi-landmarks. The
outside range quasi-landmarks can be substituted by har-
monious quasi-landmarks that are determined by the
covariance matrix of the reference model. This enables the
production of a harmonious counterpart to the patient face,
termed a ‘normal equivalent’ (NE), providing a patient-
specific control (Claes et al., 2013).
Results
The facial harmony assessments (dysmorphometrics; nor-
mal equivalent/patient presentation superimpositions)
clearly demarcated facial swellings associated with the lym-
phatic vascular malformation (Figure 1). Consistent with
the clinical presentation (Figure 2), the distance dysmor-
phogram demarcated the extent of the swelling in the left
cheek and lower lip, in particular.
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FIGURE 2
(Colour online) Profile views of texture map (digital photograph component of 3D image) of T0 pre-treatment (A) and T2 post-treatment
review (B). Note. Subtle differences can be observed with reduction in the swelling of the lips and improved facial definition.
While theminor amelioration of the anomalywas appre-
ciated clinically, the detail of the changes was revealed in the
superimpositions of mapped faces at sequential time points
in the treatment cycle (Figure 3). The initial post-treatment
review is illustrated as distancemaps of quasi-landmark dis-
cordances (Figure 3A); the reduction of swelling was highly
localized in the region of the lips and left nasolabial folds.
Further reductions were recorded at the second review time
point; however, there was awider facial distribution of these
reductions. These outcomes were also reflected in the sum-
mary statistics (Table 1) of quasi-landmark discordances
with comparative increases in the relative discordance ratio
(RSD%) and RMSE.
Discussion
We describe the first instance of 3DFA assessment of the
response of a head and neck lymphatic vascular malforma-
tion tomTOR inhibitor therapy. Specifically, usingmethods
that harmoniously assess facial form in an individualized
manner, we objectively demonstrate the extent and the re-
duction in the degree of facial anomaly (dysmorphology)
localized to the clinical site of the malformation, in concor-
dance with subjective expert clinical assessment. Notably,
while there was a clear subjective improvement of the le-
sion, as assessed by the treating physician and this child’s
parent, the degree of improvement was felt to be modest.
This might support that the resolution of our approach will
make it suitable for ascertaining milder, as well as more
marked, degrees of therapeutic response. Also, the appar-
ent, and almost circumscribed, distributionof the alteration
of facial surface morphology may provide new knowledge
about the architecture of lymphovascular compartments.
A proof of concept study for the use 3DFA for non-
invasive treatment monitoring has been reported (Kung
et al., 2013). This study’s findings give further grounds to
support additional investigation of this technique. If the
prospective utility of this approach is validated, then in se-
lected circumstances itmight be considered as a supplement
to or, at least a partial, replacement for other more costly
imaging modalities. The portability of the imaging equip-
mentmight also facilitate assessments in regional or remote
areas. In addition to monitoring apparently isolated facial
vascular anomalies, first-tier candidates for this approach
include genetic metabolic conditions with currently avail-
able therapies. Second-tier applications may include as a
secondary outcome measure in clinical trials of novel or
repurposed drugs for conditions associated with facial dys-
morphology. It is notable that the mTOR pathway interacts
with the RAS-MAPK pathway (Cargnello & Roux, 2011)
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FIGURE 3
(Colour online) Frontal, bird’s eye and profile views of distance maps of quasi-landmark discordance of the superimposition of pre-
treatment and review time points (A. T0–T1; B. T1–T2; C. T0–T2). Note. There are highly localized differences between pre-treatment
and 3 months post-treatment (T1). More global changes were observed between T1 and T2 (6 months).
TABLE 1
Summary Statistics of Quasi-Landmark Discordance Distributions
Following the Robust Superimposition of Scans at Sequential
Time Points
Time points T0–T1 T1–T2 T0–T2
Relative discordance ratio (RSD%) 9.9 9.9 12
Root mean error score (RMSE mm) 0.89 1.13 1.44
Note: TO (baseline/pre-treatment)–T1 (3 months), T1–T2 (6 months), and
T0–T2. The overall proportion of face that is discordant (RSD%)
for T0–T1 and T1–T2 is similar at 9.9%. However, visual inspection
of the superimposed scans reveals that different facial regions are
involved. The RSD% at T0–T2 is 12%. The reduction in severity of
the craniofacial anomaly is consistent with the sequential increase in
RMSE of the superimposed scans.
and that the RASopathies are a group of conditions that are
associated with mutations in this network. Clinical trials,
using repurposed oncotherapeutics, are being considered
for this class of disorders; however, the lack of objective end-
points remains a challenge. 3DFAmight offer one approach.
A further consideration is that the disruption of the
mTOR pathway has been associated with neurocognitive
disorders including autism (Crino, 2011) and 3DFA has
demonstrated patterns of facial (and brain) variation in
autistic spectrum disorders (Hammond et al., 2008). It
is possible that complementary insights into neurocog-
nitive biology may be provided by 3DFA of the mTOR
therapy response of both vascular anomalies and neurobe-
havioral phenotypes. Also, analogous to face–brain studies
in autism, further perspectives may be obtained by paired
3DFA–neuroimaging studies.
In conclusion, this report supports the treatment moni-
toring potential of 3DF and the assessment of its utility will
require further study.
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